Author: Green Apple Pharmaceuticals

🚀 Product Launch Content: Molnuheal 200 We are proud to introduce Molnuheal 200, an oral antiviral formulation containing Molnupiravir 200 mg, designed to address the urgent need for early outpatient treatment of mild to moderate COVID-19 infection in adults at high risk of disease progression. Molnuheal 200 represents a critical step in outpatient COVID-19 management—helping…

🚀 Product Launch Content: Starquin 200 We are pleased to introduce Starquin 200, a clinically trusted formulation of Hydroxychloroquine Sulphate 200 mg, developed to meet the evolving needs in the management of rheumatoid arthritis and systemic lupus erythematosus (SLE). As a cornerstone in autoimmune disease therapy, Starquin 200 delivers consistent efficacy, excellent tolerability, and long-term…

🚀 Product Launch Content: Parziworm 600 We are proud to introduce Parziworm 600, an advanced, high-strength antiparasitic formulation featuring Praziquantel 600 mg, specially designed for the treatment of tapeworm infections, Schistosomiasis, and liver fluke infestations. Backed by robust clinical evidence and global therapeutic relevance, Parziworm 600 stands as a trusted choice for healthcare professionals seeking…

🚀 Product Launch Announcement: Wormisect 500 (Fenbendazole 500 mg Tablet) We are proud to announce the launch of Wormisect 500, a powerful and clinically trusted solution in the treatment of intestinal worm infections. Engineered with Fenbendazole 500 mg, Wormisect 500 offers enhanced antiparasitic efficacy for patients requiring a high-strength, broad-spectrum anthelmintic. With the rising need…

🚀 Product Launch Content: Wormisect 444 We are proud to introduce Wormisect 444, our high-dose, next-generation solution in the fight against parasitic infections. Formulated with Fenbendazole 444 mg, this advanced oral anthelmintic is specifically designed for patients who require enhanced dosing in the management of intestinal helminths. Wormisect 444 is positioned to meet the evolving…

🚀 Product Launch: Wormisect 222 We are pleased to announce the launch of Wormisect 222, our latest pharmaceutical innovation in parasitic infection management. Formulated with Fenbendazole 222 mg, this advanced anthelmintic therapy is engineered for enhanced efficacy against a broad range of gastrointestinal worms, offering both therapeutic and preventive benefits. 🔬 Product Overview Fenbendazole is…

Product Launch: Wormisect 150 We are proud to launch Wormisect 150, a trusted anthelmintic solution formulated with Fenbendazole 150 mg, aimed at providing broad-spectrum treatment for intestinal worm infections. Designed for clinical reliability and patient safety, Wormisect 150 ensures effective parasite clearance with a proven safety profile. 🔬 About Wormisect 150 ⚙️ Mechanism of Action…

🚀 Product Launch Announcement: Tofaheal 5 (Tofacitinib 5 mg Tablets) We are pleased to announce the launch of Tofaheal 5, an advanced oral Janus kinase (JAK) inhibitor, designed to meet the therapeutic needs of patients suffering from Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ulcerative Colitis (UC). With a focus on targeted immunomodulation, Tofaheal 5…

📢 Product Launch Announcement: Tenfoday EM We are proud to announce the launch of Tenfoday EM, a fixed-dose combination of Tenofovir Disoproxil Fumarate 300 mg and Emtricitabine 200 mg, developed to support first-line antiretroviral therapy in the treatment of HIV-1 infection. This dual-action formulation represents a critical advancement in HIV management, promoting convenience, efficacy, and…

📢 Product Launch Announcement: Tenfoday 300 We are proud to introduce Tenfoday 300, a high-quality formulation containing Tenofovir Disoproxil Fumarate 300 mg, indicated for the effective management of HIV-1 infection and chronic hepatitis B.Designed with a strong focus on clinical reliability, patient safety, and treatment efficacy, Tenfoday 300 embodies our commitment to empowering healthcare professionals…